AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 262 min read$ORKA

Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift”

Oruka Therapeutics' shares rose 12% after its psoriasis drug, ORKA-001, cleared skin in 61% of high-dose patients in a Phase 2b trial, matching earlier results. The company aims for annual or biannual dosing, contrasting with competitors' more frequent regimens. Next milestones include 52-week data in December and Phase 3 trials in 2027.

Original reporting
finance.yahoo.com
Published Oct 26, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 6:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift” — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ORKABullishHigh
01

Why it matters

The Phase 2b data provides the first robust efficacy signal for a less‑frequent dosing regimen, potentially reshaping the moderate‑to‑severe psoriasis market.

02

Market read

Positive trial results are likely to drive short‑term buying in ORKA and may prompt re‑valuation of peer valuations.

03

What to watch

The trial size is modest; payer reimbursement and manufacturing scale remain uncertain.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Oruka Therapeutics (NASDAQ: ORKA) is developing ORKA‑001, a psoriasis therapy aiming for once‑or‑twice‑yearly dosing, competing with AbbVie’s Skyrizi and J&J’s Tremfya.

Company-level read

Ticker impact

$ORKABullishHigh confidence
Context

Oruka Therapeutics reported Phase 2b EVERLAST-B results showing 61% of high‑dose patients achieved PASI 100, sending the stock up 12% intraday.

Expected impact

upward pressure as the market absorbs the strong efficacy and dosing advantage.

Evidence & confidence

First disclosure of pivotal Phase 2b results for a listed biotech; data aligns with earlier trial and suggests a competitive edge, prompting immediate buying.

Market effects

Sector

Strengthens the IL‑23 inhibitor segment and may pressure peers AbbVie (ABBV) and Johnson & Johnson (JNJ) as a lower‑frequency alternative.

Regional

US biotech sector likely to see modest gains on the news.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

If long‑term efficacy or safety concerns emerge in Phase 3, the initial rally could reverse.

Key entities

  • Company
    Oruka Therapeutics

    Biotech firm developing ORKA‑001 for psoriasis.

  • Company
    AbbVie

    Manufacturer of Skyrizi, a competing IL‑23 inhibitor.

  • Company
    Johnson & Johnson

    Manufacturer of Tremfya, another competing IL‑23 inhibitor.

Read at source← All news

StoryOruka reports positive Week 16 psoriasis data and plans Phase 3 development

Also covered by

4 outlets

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min